For pharmaceutical, biotech, and life science companies in the UK, GMP and pharmacovigilance (GVP) audits are a critical part of maintaining regulatory compliance. MHRA inspections and internal audits often uncover recurring issues that can affect product quality, patient safety, and regulatory standing. Understanding the most common findings and addressing them proactively is essential to reduce inspection risks and ensure a state of continuous compliance.
This article highlights the top audit findings seen in the UK and EU, explains why they occur, and provides practical guidance on how to avoid them. Companies that act early can improve their audit outcomes, CAPA effectiveness, and regulatory confidence.
1. CAPA (Corrective and Preventive Action) Gaps
Why it happens:
MHRA inspections frequently highlight incomplete, ineffective, or delayed CAPAs. This includes CAPAs that lack proper root cause analysis, are not implemented fully, or have insufficient follow-up verification.
How to avoid it:
- Ensure CAPAs are closed on time and documented with evidence.
- Conduct thorough root cause analysis for each finding.
- Implement preventive measures and monitor their effectiveness.
- Keep a central CAPA tracking system for transparency and accountability.
Regular CAPA reviews and follow-up checks can prevent repeated findings and show regulators that your company is committed to continuous improvement.
2. Documentation and SOP Deficiencies
Why it happens:
Incomplete, outdated, or inaccessible SOPs are a common finding in both GMP and GVP audits. Inspectors may notice discrepancies between documented procedures and actual practice, missing approvals, or inconsistent version control.
How to avoid it:
- Review all SOPs at the start of the year to ensure current approval and alignment with practice.
- Implement a controlled document management system.
- Train staff regularly to ensure procedures are followed consistently.
- Include audit trails and change logs for electronic and paper-based records.
Keeping documentation accurate and up-to-date reflects a strong culture of compliance and helps reduce inspection delays.
3. Training and Competency Issues
Why it happens:
Staff who are not trained or unclear about their responsibilities can trigger audit findings. This applies to both manufacturing staff (GMP) and pharmacovigilance teams (GVP). Inspectors expect staff to understand their roles, SOPs, and regulatory requirements.
How to avoid it:
- Maintain a comprehensive training matrix.
- Conduct refresher courses on GMP, GDP, and GVP regulations.
- Ensure staff can demonstrate competency during audits or MHRA inspections.
- Document all training completion and competency assessments.
Well-trained staff not only improve inspection outcomes but also ensure day-to-day operations consistently meet regulatory standards.
4. Data Integrity Concerns
Why it happens:
Data integrity issues are increasingly common in both GMP and PV systems. Examples include incomplete records, missing audit trails, or inconsistent data entry in electronic systems or case safety reports.
How to avoid it:
- Implement robust data governance policies.
- Ensure electronic systems have access controls, audit trails, and version control.
- Conduct periodic internal audits of data integrity.
- Provide training on accurate and timely data entry, especially for ICSRs in PV systems.
Demonstrating strong data integrity processes reassures inspectors and supports overall regulatory compliance.
5. Vendor and Third-Party Oversight Weaknesses
Why it happens:
Many companies fail to adequately monitor suppliers, CMOs, CROs, or PV service providers. MHRA inspectors expect documented oversight of all critical outsourced activities.
How to avoid it:
- Conduct risk-based supplier audits regularly.
- Maintain quality agreements and SOPs for third-party oversight.
- Track vendor corrective actions and CAPAs.
- Include vendors in your inspection readiness program where relevant.
Proper vendor oversight demonstrates control over outsourced processes and reduces regulatory risks.
6. Inspection Readiness Gaps
Why it happens:
Companies may assume readiness for an MHRA inspection without testing systems under real conditions. Missing mock inspections, incomplete document access, or untrained staff can lead to findings.
How to avoid it:
- Conduct mock inspections before the real audit.
- Ensure documents and records are easily accessible.
- Prepare staff for interviews and demonstrations.
- Use independent quality oversight if internal teams are small or inexperienced.
Regular preparation and mock inspections help identify gaps early and build confidence across the organisation.
7. Pharmacovigilance System Weaknesses
Why it happens:
GVP audits often uncover gaps in safety reporting, signal management, and PSMF (Pharmacovigilance System Master File) compliance. These issues can lead to regulatory action or delays in product approvals.
How to avoid it:
- Review and maintain up-to-date PSMF documentation.
- Ensure QPPV oversight and reporting structures are clear.
- Audit internal PV processes regularly, including ICSR processing, triage, and submissions.
- Train PV staff on signal detection, case processing, and reporting deadlines.
A robust pharmacovigilance system ensures patient safety, regulatory compliance, and readiness for MHRA inspections.
Strengthening Compliance: Lessons from Common Audit Findings
Understanding common GMP and pharmacovigilance audit findings is essential for building a stronger, compliant organisation. Proactively addressing these issues helps reduce regulatory risk, improve patient safety, and show inspectors that your quality systems are well-governed.
Key lessons include:
- Plan audits early: Start the year by reviewing past findings and setting priorities.
- Maintain effective CAPAs: Implement, track, and verify corrective and preventive actions.
- Keep documentation up-to-date: SOPs and PSMFs must reflect actual practice and regulatory requirements.
- Invest in staff training: Ensure personnel fully understand their roles in GMP, GDP, and GVP processes.
- Oversee vendors and third parties: Demonstrate that outsourced activities are controlled and compliant.
- Test inspection readiness: Conduct mock inspections to identify gaps before regulators arrive.
Following these practices improves inspection outcomes, strengthens operational quality, and enhances regulatory confidence throughout the year.
Need Support with GMP and Pharmacovigilance Audits?
Quality Vigilance provides end-to-end GMP, GDP, and GVP audit services, CAPA remediation, inspection readiness support, and quality system optimisation for pharmaceutical, biotech, and life science companies across the UK and EU.
📩 Email: [email protected]
🌐 Website: www.qualityvigilance.com
📞 Phone: +44 7474 964491
Contact us today to ensure your audit and inspection readiness is fully aligned with MHRA expectations and best practices.